Q3 EPS Estimate for Viking Therapeutics Reduced by Analyst

Key Points

• Equities analysts at Leerink Partners have reduced their Q3 2025 earnings per share (EPS) estimate for Viking Therapeutics to ($0.70), down from a previous estimate of ($0.47).
• During the last quarter, Viking Therapeutics reported an EPS of (0.58), missing analysts' consensus estimate of ($0.44) by ($0.14).
• Insider trading activity saw CFO Greg Zante and CEO Brian Lian selling shares, indicating a decrease in their ownership positions in the company.

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Viking Therapeutics in a research report issued on Thursday, July 24th. Leerink Partnrs analyst T. Smith now expects that the biotechnology company will post earnings of ($0.70) per share for the quarter, down from their previous forecast of ($0.47). The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Viking Therapeutics' Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($2.46) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($4.49) EPS and FY2028 earnings at ($1.18) EPS.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.14). During the same quarter in the prior year, the business earned ($0.20) EPS. The company's revenue for the quarter was up NaN% compared to the same quarter last year.

Other equities research analysts have also recently issued reports about the stock. The Goldman Sachs Group assumed coverage on shares of Viking Therapeutics in a research report on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 price objective on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research report on Wednesday, June 25th. Raymond James Financial cut their price target on shares of Viking Therapeutics from $125.00 to $122.00 and set a "strong-buy" rating on the stock in a research report on Thursday, July 24th. Truist Financial reissued a "buy" rating and set a $75.00 price target (down from $95.00) on shares of Viking Therapeutics in a research report on Monday, April 28th. Finally, Morgan Stanley cut their price target on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Viking Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $86.92.

Viking Therapeutics Stock Down 0.6%

VKTX traded down $0.20 during trading on Monday, hitting $33.51. The company had a trading volume of 666,426 shares, compared to its average volume of 4,085,027. The company has a market capitalization of $3.77 billion, a PE ratio of -21.88 and a beta of 0.62. Viking Therapeutics has a one year low of $18.92 and a one year high of $81.73. The firm's 50-day moving average price is $28.85 and its 200 day moving average price is $28.61.

Insider Buying and Selling at Viking Therapeutics

In other Viking Therapeutics news, CEO Brian Lian sold 26,889 shares of the stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $27.80, for a total value of $747,514.20. Following the transaction, the chief executive officer directly owned 2,388,014 shares of the company's stock, valued at $66,386,789.20. This represents a 1.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Marianna Mancini sold 4,266 shares of the stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $27.77, for a total transaction of $118,466.82. Following the completion of the transaction, the chief operating officer directly owned 377,535 shares in the company, valued at approximately $10,484,146.95. This represents a 1.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 35,421 shares of company stock valued at $984,405 in the last three months. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. FIL Ltd grew its position in shares of Viking Therapeutics by 116.8% during the 4th quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 648 shares in the last quarter. Quarry LP boosted its position in Viking Therapeutics by 1,621.4% in the first quarter. Quarry LP now owns 1,205 shares of the biotechnology company's stock valued at $29,000 after buying an additional 1,135 shares in the last quarter. CIBC Private Wealth Group LLC raised its stake in shares of Viking Therapeutics by 170.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 851 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of Viking Therapeutics by 64.8% during the first quarter. Parallel Advisors LLC now owns 1,363 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 536 shares during the last quarter. Finally, Kapitalo Investimentos Ltda bought a new position in Viking Therapeutics during the fourth quarter worth $63,000. Institutional investors and hedge funds own 76.03% of the company's stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.